Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 66INDUSTRY 33NIH 10NETWORK 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 1Prostatic Neoplasms 1Prostatic Diseases 1Lung Neoplasms 1ATM Gene Mutation 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × talazoparib × Clear all
NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting
78 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT04173507 2024-09-03

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
51 enrolled 18 charts

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡